It has been demonstrated that GLP-1R/NPY2R dual agonists in vivo exert anorectic effects along with the ability to reduce blood glucose levels, thereby confirming that they could act as promising anti-obesity and antihyperglycemic agents [10]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.